Recessive protective effect of ADIPOQ rs1501299 on cardiovascular diseases with type 2 diabetes: a meta-analysis.

The association between a common variant of the ADIPOQ gene rs1501299 (+276G>T) and cardiovascular diseases (CVDs) outcomes has been reported with many studies. However, the evidence is insufficient for strong conclusions regarding CVDs and ADIPOQ rs15011299 (+276G>T). We performed a meta-analysis about the association between ADIPOQ rs1501299 (+276G>T) and CVDs risk using a predefined protocol, including 15 published studies with 5868 cases and 10,744 controls. The pooled data suggested a recessive protective effect of ADIPOQ rs1501299 (+276G>T) on CVDs for type 2 diabetes (T2D) population: the TT homozygote individuals had a reduced risk of developing CVDs compared to the carriers of G allele (OR=0.74, 95% confidence interval (CI): 0.58, 0.94; p=0.013). But there is still not enough evidence to indicate the association of the ADIPOQ rs1501299 (+276G>T) and the development of cardiovascular diseases (CVDs) outcomes in general population. In conclusion, our meta-analysis suggested that the ADIPOQ rs1501299 (+276G>T) polymorphism is a low-risk factor for the development of CVDs with T2D, but the association of this polymorphism with the susceptibility to CVDs in other populations remains unknown. It could be presumed that the ADIPOQ rs1501299 (+276G>T) be a potential cause of susceptibility to CVDs in persons with T2D, and it gives a new opportunity to investigate the mechanisms of CVDs susceptibility in T2D patients.